Aileron Therapeutics Inc Stock News

After losing some value lately, a hammer chart pattern has been formed for Aileron Therapeutics, Inc. (ALRN), indicating that the stock has found support. This, combined with an upward trend in earnin

Aileron Therapeutics, Inc. (ALRN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agr

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 2% on Tuesday. The Dow traded down 2.06% to 33,129.04 while the NASDAQ fell 2.39% to 11,506.10. The S&P

Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023. Ambrx Biopharma Inc. (NY

U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 500 points on Tuesday. The Dow traded down 1.61% to 33,280.92 while the NASDAQ fell 2.05% to 11,545.79. The S&P 5

U.S. stocks traded lower this morning, with the Nasdaq Composite dropping more than 100 points on Tuesday. Following the market opening Tuesday, The Dow traded down 1.15% to 33,438.86 while the NASDAQ

BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-

Aileron Therapeutics, Inc. (ALRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Aileron Therapeutics, Inc. (ALRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more pati

Aileron Therapeutics, Inc. (ALRN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisio

Common Stock Will Begin Trading on Split-Adjusted Basis on November 11, 2022 Common Stock Will Begin Trading on Split-Adjusted Basis on November 11, 2022

Aileron Therapeutics, Inc. (ALRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more pati

BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer pati